JPH10101575A - 骨折治療剤及び骨折の治療方法 - Google Patents
骨折治療剤及び骨折の治療方法Info
- Publication number
- JPH10101575A JPH10101575A JP9060084A JP6008497A JPH10101575A JP H10101575 A JPH10101575 A JP H10101575A JP 9060084 A JP9060084 A JP 9060084A JP 6008497 A JP6008497 A JP 6008497A JP H10101575 A JPH10101575 A JP H10101575A
- Authority
- JP
- Japan
- Prior art keywords
- parathyroid hormone
- bone
- ovx
- fracture
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 208000010392 Bone Fractures Diseases 0.000 title abstract description 44
- 238000000034 method Methods 0.000 title abstract description 20
- 108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 70
- 102000003982 Parathyroid hormone Human genes 0.000 claims abstract description 68
- 239000000199 parathyroid hormone Substances 0.000 claims abstract description 68
- 229960001319 parathyroid hormone Drugs 0.000 claims abstract description 60
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 claims abstract description 3
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 claims abstract description 3
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 3
- 239000013612 plasmid Substances 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 229940088597 hormone Drugs 0.000 claims description 22
- 239000005556 hormone Substances 0.000 claims description 22
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 abstract description 32
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 6
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 239000002075 main ingredient Substances 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 206010017076 Fracture Diseases 0.000 description 59
- 210000001672 ovary Anatomy 0.000 description 41
- 208000001132 Osteoporosis Diseases 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 230000002611 ovarian Effects 0.000 description 11
- 238000002271 resection Methods 0.000 description 11
- 238000009806 oophorectomy Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 4
- 210000002990 parathyroid gland Anatomy 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000001195 anabolic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102100036893 Parathyroid hormone Human genes 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 206010034023 Parotid gland enlargement Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000373 effect on fracture Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR41162 | 1996-09-20 | ||
| KR1019960041162A KR100283138B1 (ko) | 1996-09-20 | 1996-09-20 | 골절 치료제 및 골절의 치료 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10101575A true JPH10101575A (ja) | 1998-04-21 |
Family
ID=19474558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9060084A Pending JPH10101575A (ja) | 1996-09-20 | 1997-02-28 | 骨折治療剤及び骨折の治療方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPH10101575A (ko) |
| KR (1) | KR100283138B1 (ko) |
-
1996
- 1996-09-20 KR KR1019960041162A patent/KR100283138B1/ko not_active IP Right Cessation
-
1997
- 1997-02-28 JP JP9060084A patent/JPH10101575A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR960040373A (ko) | 1996-12-17 |
| KR100283138B1 (ko) | 2001-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100306852B1 (ko) | 골량을 증가시키기위한 부갑상선호르몬 및 랄옥시펜 | |
| AU2003287423B2 (en) | Methods and systems for enabling and stabilizing tooth movement | |
| JP5086322B2 (ja) | Ｍｃｐ−１プロテインの増加生産によって特徴付けられる障害の処置のための薬剤組成物 | |
| JP2007537281A (ja) | 骨形成の促進方法と維持 | |
| ITRM960790A1 (it) | Uso di sostanze che attivano il recettore del cntf ( fattore neurotro fico ciliare) per la preparazione di farmaci per la terapia della | |
| AU9219298A (en) | Method of increasing bone volume using non-naturally-occurring fp selective agonists | |
| AU753477B2 (en) | A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor | |
| JP3771280B2 (ja) | オステオポローシスの治療方法およびそのための組成物 | |
| CN1460482A (zh) | 一种含淫羊藿素、去甲基淫羊藿素的药物组合物及其用途 | |
| US20030166631A1 (en) | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | |
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| RU2107512C1 (ru) | Фармацевтическая композиция для остеоиндукции, способ генерации новой кости | |
| RU2003136733A (ru) | Пероральное введение паратиреоидного гормона и кальцитонина | |
| EP1721617A2 (en) | Dental therapeutics containing parathyroid hormone | |
| JPH10101575A (ja) | 骨折治療剤及び骨折の治療方法 | |
| JPH0873376A (ja) | 骨粗鬆症治療薬 | |
| US20060165799A1 (en) | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers | |
| JP2003095974A (ja) | 骨形成を安全に促進させる医薬複合剤 | |
| JP2010526064A (ja) | 骨組織の成長の育成および保存のための方法および組成物 | |
| JP2001503728A (ja) | 骨粗鬆症治療用のエストロゲン及び副甲状腺ホルモン | |
| RU2808878C1 (ru) | Фармацевтическая комбинация для стимуляции регенерации костной ткани и способ ее использования | |
| JP5300943B2 (ja) | 骨形成を安全に促進させる医薬複合剤 | |
| JP2002538105A (ja) | 骨体積の増加のための天然に存在しないｅｐ１選択的アゴニストの使用 | |
| RU2155588C2 (ru) | Способ увеличения массы костной ткани при переломах | |
| SK3402000A3 (en) | Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject |